Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole pollen extract and placebos

Philip S. Norman, Walter L. Winkenwerder, Lawrence M. Lichtenstein

Research output: Contribution to journalArticle

Abstract

Preseasonal immunotherapy of ragweed hay fever with the major allergen of ragweed pollen, antigen E, has been tested in double-blind controlled comparisons with whole extract of ragweed and placebos over a period of four years. Antigen E was well tolerated by ragweed-sensitive patients, giving fewer systemic and local reactions than whole extract. As a result, greater quantities of antigen E could be administered in its purified form than could be given in whole extract. Gradually increasing doses of antigen E were given preseasonally each year as this relative safety became apparent. Therapeutic results were significantly better than the results of placebo injections in the third and fourth years of trial when the antigen E-treated patients received an average preseasonal dose of 252 and 743 mcg., respectively. These results were similar to those obtained in patients treated with whole ragweed extract in the same years with average doses of 2,440 and 9,480 PNU, respectively. Whether similar doses can be administered with as good a result in the first year of treatment remains to be tested. It seems likely that a major proportion of the desensitizing effect of whole extract can be attributed to antigen E.

Original languageEnglish (US)
Pages (from-to)93-108
Number of pages16
JournalJournal of Allergy
Volume42
Issue number2
StatePublished - Aug 1968

Fingerprint

Seasonal Allergic Rhinitis
Ambrosia
Pollen
Immunotherapy
Placebos
Antigens
Allergens
Ambrosia artemisiifolia Amb a I protein
Safety
Injections
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunotherapy of hay fever with ragweed antigen E : Comparisons with whole pollen extract and placebos. / Norman, Philip S.; Winkenwerder, Walter L.; Lichtenstein, Lawrence M.

In: Journal of Allergy, Vol. 42, No. 2, 08.1968, p. 93-108.

Research output: Contribution to journalArticle

Norman, Philip S. ; Winkenwerder, Walter L. ; Lichtenstein, Lawrence M. / Immunotherapy of hay fever with ragweed antigen E : Comparisons with whole pollen extract and placebos. In: Journal of Allergy. 1968 ; Vol. 42, No. 2. pp. 93-108.
@article{c965008bf7454c809670ce800bf5a6d6,
title = "Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole pollen extract and placebos",
abstract = "Preseasonal immunotherapy of ragweed hay fever with the major allergen of ragweed pollen, antigen E, has been tested in double-blind controlled comparisons with whole extract of ragweed and placebos over a period of four years. Antigen E was well tolerated by ragweed-sensitive patients, giving fewer systemic and local reactions than whole extract. As a result, greater quantities of antigen E could be administered in its purified form than could be given in whole extract. Gradually increasing doses of antigen E were given preseasonally each year as this relative safety became apparent. Therapeutic results were significantly better than the results of placebo injections in the third and fourth years of trial when the antigen E-treated patients received an average preseasonal dose of 252 and 743 mcg., respectively. These results were similar to those obtained in patients treated with whole ragweed extract in the same years with average doses of 2,440 and 9,480 PNU, respectively. Whether similar doses can be administered with as good a result in the first year of treatment remains to be tested. It seems likely that a major proportion of the desensitizing effect of whole extract can be attributed to antigen E.",
author = "Norman, {Philip S.} and Winkenwerder, {Walter L.} and Lichtenstein, {Lawrence M.}",
year = "1968",
month = "8",
language = "English (US)",
volume = "42",
pages = "93--108",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Immunotherapy of hay fever with ragweed antigen E

T2 - Comparisons with whole pollen extract and placebos

AU - Norman, Philip S.

AU - Winkenwerder, Walter L.

AU - Lichtenstein, Lawrence M.

PY - 1968/8

Y1 - 1968/8

N2 - Preseasonal immunotherapy of ragweed hay fever with the major allergen of ragweed pollen, antigen E, has been tested in double-blind controlled comparisons with whole extract of ragweed and placebos over a period of four years. Antigen E was well tolerated by ragweed-sensitive patients, giving fewer systemic and local reactions than whole extract. As a result, greater quantities of antigen E could be administered in its purified form than could be given in whole extract. Gradually increasing doses of antigen E were given preseasonally each year as this relative safety became apparent. Therapeutic results were significantly better than the results of placebo injections in the third and fourth years of trial when the antigen E-treated patients received an average preseasonal dose of 252 and 743 mcg., respectively. These results were similar to those obtained in patients treated with whole ragweed extract in the same years with average doses of 2,440 and 9,480 PNU, respectively. Whether similar doses can be administered with as good a result in the first year of treatment remains to be tested. It seems likely that a major proportion of the desensitizing effect of whole extract can be attributed to antigen E.

AB - Preseasonal immunotherapy of ragweed hay fever with the major allergen of ragweed pollen, antigen E, has been tested in double-blind controlled comparisons with whole extract of ragweed and placebos over a period of four years. Antigen E was well tolerated by ragweed-sensitive patients, giving fewer systemic and local reactions than whole extract. As a result, greater quantities of antigen E could be administered in its purified form than could be given in whole extract. Gradually increasing doses of antigen E were given preseasonally each year as this relative safety became apparent. Therapeutic results were significantly better than the results of placebo injections in the third and fourth years of trial when the antigen E-treated patients received an average preseasonal dose of 252 and 743 mcg., respectively. These results were similar to those obtained in patients treated with whole ragweed extract in the same years with average doses of 2,440 and 9,480 PNU, respectively. Whether similar doses can be administered with as good a result in the first year of treatment remains to be tested. It seems likely that a major proportion of the desensitizing effect of whole extract can be attributed to antigen E.

UR - http://www.scopus.com/inward/record.url?scp=0014315961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014315961&partnerID=8YFLogxK

M3 - Article

C2 - 4873833

AN - SCOPUS:0014315961

VL - 42

SP - 93

EP - 108

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -